A preclinical model of binge eating elicited by yo-yo dieting and stressful exposure to food: effect of sibutramine, fluoxetine, topiramate, and midazolam
Preclinical models are needed to investigate the neurobiology and psychobiology of binge eating and to identify innovative pharmacotherapeutic strategies.
A modification of the model based on the combination of cyclic caloric restrictions and acute stress was developed to further increase its face validity and reliability and, for the first time, to assess its predictive value.
Materials and methods
Four groups of female rats were employed: group 1 was normally fed and not stressed on the test day (25th); group 2 was fed normally but was exposed to an acute stress on day 25; group 3 was exposed to three cycles (4 days 66% of chow intake + 4 days food ad libitum) of yo-yo dieting but not stressed; and group 4 was exposed to cyclic yo-yo dieting and then stressed. All groups were fed highly palatable food (HPF) for 2 h on days 5–6 and 13–14. Acute stress was elicited by exposing rats to HPF, but preventing them from access to it for 15 min.
The combination of cyclic food restriction and stressful exposure to food markedly increased HPF intake. Sibutramine and fluoxetine inhibited food intake in all conditions. Topiramate selectively inhibited compulsive HPF intake in rats submitted to caloric restriction and stress. Midazolam increased HPF intake.
Pharmacological results suggest that this model, in addition to face validity as an isomorphic model of human binge eating, is endowed with good predictive validity.
KeywordsBinge eating Caloric restriction Environmental stress Palatable food Sibutramine Fluoxetine Topiramate Midazolam Female rats
This study was supported by the MURST, Rome, Italy (PRIN 2006 to M. Massi).
- American Psychiatric Association (2000) Diagnostic and statistic manual of mental disorders, IV-TR. APA, Washington, DCGoogle Scholar
- Hansson AC, Cippitelli A, Sommer WH, Fedeli A, Bjork K, Soverchia L, Terasmaa A, Massi M, Heilig M, Ciccocioppo R (2006) Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress. Proc Natl Acad Sci U S A 103:15236–15241PubMedCrossRefGoogle Scholar
- Johannessen Landmark C (2007) Targets for antiepileptic drugs in the synase. Med Sci Monit 13:RA1–RA7Google Scholar
- McElroy SL, Shapira NA, Arnold LM, Keck PE, Rosenthal NR, Wu SC et al (2004) Topiramate in the long-term treatment of binge eating disorder associated with obesity. J Clin Psychiatry 65:1453–1469Google Scholar
- National Institute for Clinical Excellence (2004) Eating disorders—core interventions in the treatment and management of anorexia nervosa, bulimia nervosa, and related eating disorders. National Institute for Clinical Excellence, LondonGoogle Scholar
- Resis AD, Castro LA, Faria R, Laranjeira R (2008) Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. Rev Bras Psiquiatr 30:132–135Google Scholar
- Robbins TW, Fray PJ (1980) Stress-induced eating: fact, fiction or misunderstanding. Appetite 1:103–133Google Scholar
- Spitzer RL, Stunkard A, Yanovski S, Marcus MD, Wadden T, Wing R, Mitchell J, Hasin D (1993) Binge eating disorder should be included in DSM-IV: a reply to Fairburn et al.’s “the classification of recurrent overeating: the binge eating disorder proposal”. Int J Eat Disord 13:161–169PubMedCrossRefGoogle Scholar
- Wilfley DE, Crow SJ, Hudson JI, Mitchell JE, Berkowitz RI, Blakesley V, Walsh BT (2008) Sibutramine eating disorder research Group. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry 165:51–58PubMedCrossRefGoogle Scholar
- Willner P (1991) Behavioural models in psychopharmacology. In: Willner P (ed) Behavioural models in psychopharmacology. Cambridge University Press, Cambridge, pp 3–18Google Scholar
- Yanovski SZ (1993) Binge eating disorder: current knowledge and future directions. Obes Res 1:4163–4169Google Scholar